While esophageal cells have been shown to upregulate CXCL10 after IL-17 stimulation [34], whether IL-17A and IL-17F directly upregulate CXCL10 during NAFLD progression remains unexamined. This evidence concerns the gene IL17A and metabolic dysfunction-associated steatotic liver disease.